Merck’s Mevacor not approved
This article was originally published in The Tan Sheet
Executive Summary
FDA found Merck's third Rx-to-OTC switch application for OTC cholesterol-lowering Mevacor Daily (lovastatin/20mg) "not approvable." In a Jan. 25 release, the firm said FDA's letter responding to its application indicated the drug's approval would require "a revised label and additional data from Merck in order to gain marketing approval." "We are evaluating the conditions put forth by the agency in the letter to determine a path forward, and no decision is made at this time for the future of our Mevacor efforts," a spokesman forthe Whitehouse, N.J.-based firm told "The Tan Sheet." At a Dec. 13 meeting, FDA advisory committees recommended against approving the switch. The firm was also unsuccessful in gaining OTC approval for the drug in 2000 and 2005.....
You may also be interested in...
Pediatric CVD Report Slights Nutrition’s Role, Weighs On OTC Statin Chances
An American Academy of Pediatrics report recommending prescribing statin drugs for cardiovascular disease in children could present another roadblock for switching statins to OTC
FDA Rules Insufficient For Statins, Chronic Switches – Former NDAC Chair
Future attempts to switch drugs for chronic, asymptomatic conditions to OTC status could be stymied unless new authorities are granted to FDA, says the chairwoman who oversaw the most recent Nonprescription Drugs Advisory Committee meeting to review a statin switch application
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.